

Policy Name:	Corlanor (ivabradine)	Policy #:	2350P
---------------------	------------------------------	------------------	--------------

Purpose of the Policy

The purpose of this policy is to define the criteria in place for Corlanor.

Statement of the Policy

Health Alliance Medical Plans will approve the use of Corlanor when the following criteria have been met.

Criteria

1. Coverage Criteria for Heart Failure

- 1.1 Diagnosis of persistent heart failure (NYHA class II-III) with left ventricular ejection fraction $\leq 35\%$, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute
- 1.2 Prescribed by a cardiologist (heart doctor)
- 1.3 Documented failure, intolerance, or contraindication to a beta blocker, such as atenolol or metoprolol,
- 1.4 Documented failure, intolerance, or contraindication to an angiotensin converting enzyme inhibitor (ACE-I, such as lisinopril or enalapril), OR an angiotensin II receptor blocker (ARB, such as losartan or candesartan)

2. Coverage Criteria for Inappropriate Sinus Tachycardia

- 2.1 Prescribed by an electrophysiologist (doctor specializing in electrical activity of the heart)

3. Approval Period

- 3.1 Initial Approval: 12 months
- 3.2 Subsequent Approvals: 2 years

CPT Codes

HCPCS Codes

References

1. Corlanor (ivabradine) [prescribing information]. Thousand Oaks, CA: Amgen Inc; August 2021.
2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022 May 3;145(18):e895-e1032.
3. Cappato R, Castelvechchio S, Ricci C, Bianco E, Vitali-Serdoz L, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. *J Am Coll Cardiol*. 2012;60(15):1323-1329.
4. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2015. pii: S0735-1097(15)05840-4.

Created Date: 06/03/15
Effective Date: 06/03/15
Posted to Website: 01/01/22
Revision Date: 06/05/24

DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.